secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2025-07-07T23:59:59+00:00
Accession:  0001104659-25-065926
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee: Phase 2 APG777 hits all endpoints; EASI-75 66.9% (42.5% placebo-adjusted), safety favorable
--------------------------------------------------------------------------------

- APEX Part A met primary endpoint: 71% mean EASI reduction vs 33.8% placebo (p<0.001).
- EASI-75 achieved by 66.9% of APG777 patients vs 24.6% placebo (p<0.001); highest of any biologic in global study.
- Rapid itch relief: 50.7% reduction in Itch NRS at Week 1 (p<0.01). Safety well-tolerated, no injection site reactions.
- Exposure-response: top quartiles had 83-89% EASI-75; Part B testing higher dose, readout mid-2026.
- 52-week maintenance data expected 1H 2026; APG279 Phase 1b vs DUPIXENT dosed, readout 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925065926/0001104659-25-065926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925065926/tm2519512d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-065926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer